Teleflex is separating into two publicly traded companies to optimize growth and shareholder value. The acquisition of Biotronik's Vascular Intervention expands Teleflex's presence in coronary and ...
Teleflex Incorporated has announced its agreement to acquire most of the Vascular Intervention business from BIOTRONIK SE & Co. KG for approximately €760 million, pending regulatory approvals ...
Teleflex announced a major strategic pivot, planning to separate into two independent publicly traded companies to maximize shareholder value. The separation, expected to complete by mid-2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback